The Food and Drug Administration “lacks a clear and effective process” for managing postmarket drug safety issues, says a Government Accountability Office report out Monday. The report was requested in late 2004 by Sen. Charles Grassley, R-Iowa, chair of the Senate Finance Committee, and Rep. Joe Barton, R-Texas, chair of the House Energy and Commerce Committee.
